Drug giant pulls plug on Exubera
NEW YORK - Pfizer will stop selling its inhaled insulin drug Exubera less than two years after introducing it, the drug giant announced in October. Sales of the drug amounted to less than 1% of the insulin market, the New York Times reported. Pfizer will take a charge of $2.8 billion for costs associated with Exubera, making it one of the most expensive failures in the history of the pharmaceutical industry, the newspaper reported. A diabetes specialist told the New York Times that inhaled insulin is "just not a practical way to treat" diabetics.